Key result
Sirolimus is supported for the treatment of patients with multifocal epithelioid hemangioendothelioma without serosal effusion.
Why the study?
Epithelioid hemangioendothelioma is an ultrarare soft tissue sarcoma with limited literature to guide treatment.
Key points are not available for this paper at this time.
Population
Patients with progressive epithelioid hemangioendothelioma
Comparison
Sirolimus
Design
Retrospective cohort study
May guide sirolimus consideration in rare multifocal EHE; leaves open need for randomized confirmation.
Epithelioid hemangioendothelioma is an ultrarare soft tissue sarcoma with limited literature to guide treatment. The results from a robust retrospective cohort study support the use of sirolimus for patients who have multifocal epithelioid hemangioendothelioma without serosal effusion.
No takes yet. Share an insight, caveat, or question.
Smrke et al. (2020) studied this question. Sirolimus is supported for the treatment of patients with multifocal epithelioid hemangioendothelioma without serosal effusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: